Francis Arenas, MD
Internal Medicine · Bakersfield, CANPI 1275717647
Payments from drug & device makers
Across 441 payments — averaging $15.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Amgen$1K
- AstraZeneca$580
- Lilly USA, LLC$487
- Aimmune Therapeutics, Inc.$436
- AbbVie$423
- plus $2K from 32 others
What the payments were for
- Food & beverage$6,88799%
- Education$491%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 150 | $1,832 |
| Amgen(2 entities) | 64 | $1,198 |
| AstraZeneca | 36 | $580 |
| Lilly USA, LLC | 11 | $487 |
| Aimmune Therapeutics, Inc. | 49 | $436 |
| AbbVie(2 entities) | 29 | $423 |
| Radius Health, Inc. | 9 | $210 |
| Kowa Pharmaceuticals America, Inc. | 5 | $139 |
| Boehringer Ingelheim | 7 | $139 |
| Merck | 8 | $133 |
| Amarin Pharma, Inc. | 7 | $127 |
| Scilex Pharmaceuticals Inc. | 8 | $110 |
| Novartis | 5 | $102 |
| Abbott | 6 | $101 |
| Pfizer | 6 | $89 |
| Sanofi-aventis U.S. LLC | 5 | $77 |
| Akcea Therapeutics, Inc. | 1 | $71 |
| Dexcom, Inc. | 4 | $68 |
| Vivus LLC | 1 | $65 |
| Nestle Healthcare Nutrition Inc. | 3 | $60 |
| Bayer | 2 | $45 |
| Nevro Corp. | 3 | $45 |
| Biosense Webster, Inc. | 1 | $43 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $42 |
| Ironwood Pharmaceuticals, Inc | 3 | $41 |
| Corcept Therapeutics | 2 | $37 |
| Eisai Inc. | 2 | $36 |
| Medtronic | 1 | $34 |
| GSK | 2 | $26 |
| Idorsia Pharmaceuticals US Inc | 1 | $24 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| Supernus Pharmaceuticals, Inc. | 1 | $18 |
| Insulet Corporation | 1 | $17 |
| Organon | 1 | $13 |
| Johnson & Johnson | 1 | $13 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $12 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
| Vifor Pharma, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,936 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 290 | $204,393 |
| OzempicSemaglutide | 181 | $168,577 |
| JardianceEmpagliflozin | 87 | $76,730 |
| ProliaDenosumab | 34 | $55,928 |
| EliquisApixaban | 56 | $46,474 |
| JanuviaSitagliptin Phosphate | 54 | $39,946 |
| RybelsusSemaglutide | 35 | $39,100 |
| TradjentaLinagliptin | 49 | $38,380 |
| SynjardyEmpagliflozin/Metformin Hcl | 45 | $33,757 |
| Teriparatide | 14 | $31,603 |
| JanumetSitagliptin Phos/Metformin Hcl | 40 | $29,612 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 52 | $25,810 |
| LinzessLinaclotide | 39 | $19,936 |
| XareltoRivaroxaban | 21 | $17,664 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $15,576 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $580 | $212,593304 claims |
| Novo NordiskOzempic, Rybelsus | $1,832 | $207,677216 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy | $139 | $148,867181 claims |
| MerckJanuvia, Janumet, Janumet Xr | $133 | $72,345105 claims |
| AmgenProlia | $1,198 | $55,92834 claims |
| PfizerEliquis | $89 | $46,47456 claims |
| AbbVieLinzess | $423 | $19,93639 claims |
| Johnson & JohnsonXarelto | $13 | $17,66421 claims |
| Lilly USA, LLCMounjaro | $487 | $12,09112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.
Other internal medicine in Bakersfield
- Andrew ChengSouth San Francisco$55.1M
- Joel NeutelTustin$34.9M
- Donald BrandonSan Diego$34M
- William TownerLos Angeles$27.4M
- Rahul AggarwalSan Francisco$24M
- Masoud AzizadNorthridge$21.1M
- Helen StaceyWalnut Creek$20.4M
- Rohit Loombala Jolla$15.1M
- Zeid KayaliColton$14.2M
- Alexandra DrakakiSanta Monica$14.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.